Maze Therapeutics Inc(US:MAZE)2025-08-12 20:06Financial Position - Maze Therapeutics reported a cash position of $264.5 million as of June 30, 2025, up from $196.8 million as of December 31, 2024, providing a cash runway into H2 2027[6]. - Total liabilities as of June 30, 2025, were $41.3 million, down from $43.6 million as of December 31, 2024[18]. Revenue and Expenses - The company recognized no license revenue for the three and six months ended June 30, 2025, compared to $165.0 million for the same periods in 2024, primarily due to an upfront payment from Shionogi[7][10]. - Research and Development (R&D) expenses increased to $28.1 million for Q2 2025, compared to $19.5 million in Q2 2024, reflecting higher clinical trial and manufacturing costs[8]. - General and Administrative (G&A) expenses rose to $8.4 million for Q2 2025, compared to $5.9 million in Q2 2024, driven by higher personnel-related expenses[9]. - The net loss for the three months ended June 30, 2025, was $33.7 million, compared to a net income of $139.1 million for the same period in 2024, largely due to the absence of license revenue[10]. Clinical Trials and Pipeline - MZE782 is currently in a Phase 1 trial, with initial data expected in Q3 2025, aimed at treating chronic kidney disease (CKD) and phenylketonuria (PKU)[12]. - The Phase 2 HORIZON trial for MZE829 is actively enrolling patients, with initial proof-of-concept data anticipated in Q1 2026[5][2]. - MZE829 targets APOL1-mediated kidney disease, which affects over one million people in the U.S.[3]. - Maze's pipeline includes MZE782, which targets SLC6A19, potentially benefiting approximately five million U.S. patients with CKD[4].